Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

RICHARD R FURMAN

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1770670861
CMS profile
125515
Location
NEW YORK, NY

General Payments · PY2018–2024

$225,747.87

  • Reported across 171 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$44,654.57

35 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $41,122.70 10
Travel and Lodging $2,089.99 7
Food and Beverage $1,441.88 18

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
BeiGene USA, Inc. $19,620.26 12
GENZYME CORPORATION $11,846.20 11
Acerta Pharma LLC $7,725.00 3
Eli Lilly and Company $4,000.00 1
Ipsen Innovation $870.00 1
ABBVIE INC. $275.94 4
Apellis Pharmaceuticals, Inc. $135.00 1
Janssen Scientific Affairs, LLC $117.17 1
Genmab U.S., Inc. $65.00 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $35,277.39 34
PY2019 $22,275.48 20
PY2020 $40,534.35 17
PY2021 $42,696.40 17
PY2022 $27,777.28 23
PY2023 $12,532.40 25
PY2024 $44,654.57 35

Payment records · PY2024 (35)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
ABBVIE INC. $11.56 02/06/2024 Food and Beverage Undisputed 01/23/2026 1103761600 CMS
ABBVIE INC. $7.80 02/26/2024 Food and Beverage Undisputed 01/23/2026 1103761602 CMS
ABBVIE INC. $115.21 10/30/2024 Food and Beverage Undisputed 01/23/2026 1103761604 CMS
ABBVIE INC. $141.37 12/05/2024 Food and Beverage Undisputed 01/23/2026 1103761606 CMS
Apellis Pharmaceuticals, Inc. $135.00 11/07/2024 Food and Beverage Undisputed 01/23/2026 1154028203 CMS
AstraZeneca Pharmaceuticals LP $4,795.00 07/22/2024 Consulting Fee Undisputed 01/23/2026 1105445468 CMS
AstraZeneca Pharmaceuticals LP $60.00 12/09/2024 Food and Beverage Undisputed 01/23/2026 1105793724 CMS
AstraZeneca Pharmaceuticals LP $2,870.00 12/19/2024 Consulting Fee Undisputed 01/23/2026 1105752883 CMS
BeiGene USA, Inc. $1,500.00 01/12/2024 Consulting Fee Undisputed 01/23/2026 1120844476 CMS
BeiGene USA, Inc. $151.93 02/23/2024 Travel and Lodging Undisputed 01/23/2026 1120844472 CMS
BeiGene USA, Inc. $139.14 03/19/2024 Food and Beverage Undisputed 01/23/2026 1120844464 CMS
BeiGene USA, Inc. $39.71 03/19/2024 Food and Beverage Undisputed 01/23/2026 1120844467 CMS
BeiGene USA, Inc. $866.20 03/19/2024 Travel and Lodging Undisputed 01/23/2026 1120844483 CMS
BeiGene USA, Inc. $418.70 04/23/2024 Consulting Fee Undisputed 01/23/2026 1120844455 CMS
BeiGene USA, Inc. $8,250.00 04/23/2024 Consulting Fee Undisputed 01/23/2026 1120844459 CMS
BeiGene USA, Inc. $1,875.00 06/28/2024 Consulting Fee Undisputed 01/23/2026 1120844451 CMS
BeiGene USA, Inc. $142.13 10/01/2024 Food and Beverage Undisputed 01/23/2026 1120844497 CMS
BeiGene USA, Inc. $124.31 12/08/2024 Food and Beverage Undisputed 01/23/2026 1120844479 CMS
BeiGene USA, Inc. $113.14 12/09/2024 Food and Beverage Undisputed 01/23/2026 1120844492 CMS
BeiGene USA, Inc. $6,000.00 12/18/2024 Consulting Fee Undisputed 01/23/2026 1120844488 CMS
Eli Lilly and Company $4,000.00 02/02/2024 Consulting Fee Undisputed 01/23/2026 1135388279 CMS
Genmab U.S., Inc. $65.00 12/07/2024 Food and Beverage Undisputed 01/23/2026 1126831172 CMS
GENZYME CORPORATION $328.02 02/17/2024 Travel and Lodging Undisputed 01/23/2026 1139973397 CMS
GENZYME CORPORATION $280.34 02/17/2024 Travel and Lodging Undisputed 01/23/2026 1139973399 CMS
GENZYME CORPORATION $296.21 02/17/2024 Travel and Lodging Undisputed 01/23/2026 1139973401 CMS
GENZYME CORPORATION $46.43 02/17/2024 Food and Beverage Undisputed 01/23/2026 1139973403 CMS
GENZYME CORPORATION $38.66 02/17/2024 Food and Beverage Undisputed 01/23/2026 1139973405 CMS
GENZYME CORPORATION $77.39 02/17/2024 Food and Beverage Undisputed 01/23/2026 1139973407 CMS
GENZYME CORPORATION $36.23 02/17/2024 Food and Beverage Undisputed 01/23/2026 1139973409 CMS
GENZYME CORPORATION $10,544.00 02/17/2024 Consulting Fee Undisputed 01/23/2026 1139973411 CMS
GENZYME CORPORATION $31.63 02/17/2024 Food and Beverage Undisputed 01/23/2026 1139973413 CMS
GENZYME CORPORATION $133.29 02/17/2024 Travel and Lodging Undisputed 01/23/2026 1139973415 CMS
GENZYME CORPORATION $34.00 02/17/2024 Travel and Lodging Undisputed 01/23/2026 1139973417 CMS
Ipsen Innovation $870.00 01/12/2024 Consulting Fee Undisputed 01/23/2026 1071126340 CMS
Janssen Scientific Affairs, LLC $117.17 07/31/2024 Food and Beverage Undisputed 01/23/2026 1078855532 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.